What does this research mean for the field?

The genetic architecture of epilepsy involves multiple interacting layers of genomic variation—including rare variants, polygenic risk, and somatic mosaicism—that converge on core biological pathways to drive seizure susceptibility and clinical diversity. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

August 22, 2026Epilepsia OpenOpen Access

The genetic architecture of epilepsy across molecular mechanisms and clinical heterogeneity

View Full Paper

Ask AI

Bookmark

Authors

MSMohammad Reza Seyedtaghia JBJina Babanzadeh MSMarcello Scala

Discussion

Member takes

Overview

Review uncovers multilayered genetic and molecular pathways in epilepsy, highlighting opportunities for targeted precision therapies and personalized clinical management.

Key Points

Synthesize contemporary evidence on the multilayered genetic architecture, molecular mechanisms, and clinical heterogeneity underlying epilepsy to inform precision diagnostic and therapeutic strategies.
Reviewed literature on genomic variation in epilepsy, integrating monogenic variants, polygenic risk factors, somatic mosaicism, and gene-environment interactions.
Analyzed biological pathways destabilizing excitation-inhibition balance, including ion channel dysfunction, synaptic vesicle cycling defects, mTOR hyperactivation, and neuroinflammation.
Evaluated clinical translation across seizure phenotypes, penetrance, pleiotropy, pharmacogenomics, and emerging molecular therapies.
Demonstrated that epilepsy risk converges on core biological networks regulating neuronal excitability, synaptic transmission, glial function, metabolic homeostasis, and circuit remodeling.
Identified that clinical heterogeneity in age of onset, seizure semiology, and pharmacoresistance is heavily driven by complex interactions between rare high-penetrance variants, polygenic background modifiers, and brain-restricted somatic mutations.
Highlighted emerging precision medicine platforms, including antisense oligonucleotides, gene regulation tools, and cell-based therapeutics aimed at targeted pathophysiological mechanisms.

Cite This Study

Seyedtaghia et al. (2026) studied this question.

synapsesocial.com/papers/6a895eeeca7ade938187d2bc https://doi.org/10.1002/epi4.70310

View Full Paper

Ask AI

Bookmark

August 22, 2026Epilepsia OpenOpen Access

The genetic architecture of epilepsy across molecular mechanisms and clinical heterogeneity

View Full Paper

Ask AI

Bookmark

Authors

MSMohammad Reza Seyedtaghia JBJina Babanzadeh MSMarcello Scala

Discussion

Member takes

Overview

Review uncovers multilayered genetic and molecular pathways in epilepsy, highlighting opportunities for targeted precision therapies and personalized clinical management.

Key Points

Synthesize contemporary evidence on the multilayered genetic architecture, molecular mechanisms, and clinical heterogeneity underlying epilepsy to inform precision diagnostic and therapeutic strategies.
Reviewed literature on genomic variation in epilepsy, integrating monogenic variants, polygenic risk factors, somatic mosaicism, and gene-environment interactions.
Analyzed biological pathways destabilizing excitation-inhibition balance, including ion channel dysfunction, synaptic vesicle cycling defects, mTOR hyperactivation, and neuroinflammation.
Evaluated clinical translation across seizure phenotypes, penetrance, pleiotropy, pharmacogenomics, and emerging molecular therapies.
Demonstrated that epilepsy risk converges on core biological networks regulating neuronal excitability, synaptic transmission, glial function, metabolic homeostasis, and circuit remodeling.
Identified that clinical heterogeneity in age of onset, seizure semiology, and pharmacoresistance is heavily driven by complex interactions between rare high-penetrance variants, polygenic background modifiers, and brain-restricted somatic mutations.
Highlighted emerging precision medicine platforms, including antisense oligonucleotides, gene regulation tools, and cell-based therapeutics aimed at targeted pathophysiological mechanisms.

Cite This Study

Seyedtaghia et al. (2026) studied this question.

synapsesocial.com/papers/6a895eeeca7ade938187d2bc https://doi.org/10.1002/epi4.70310

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark